军事知识服务平台
B7同源物3表达与卵巢癌肿瘤免疫微环境及患者预后关系的探讨
Association of B7-H3 expression with tumor immune microenvironment and prognosis in patients with ovarian cancer
摘要 目的:分析B7同源物3(B7-H3)在卵巢上皮性癌(卵巢癌)组织中的表达水平及其与患者临床病理特征、无进展生存(PFS)时间及免疫细胞亚群浸润水平的关系。方法:选取2020年9月至2024年12月南京医科大学第一附属医院收治的192例卵巢癌患者。采用免疫组化法检测卵巢癌组织中B7-H3的表达水平,单因素及多因素Cox回归分析B7-H3表达水平与患者临床病理特征的关系,并评估其对卵巢癌患者PFS时间的影响。通过多重免疫荧光(mIF)技术分析不同免疫细胞亚群的浸润水平及其与B7-H3表达的相关性。结果:(1)卵巢癌组织中B7-H3的总阳性率为92.1%(177/192),其表达在不同组织学亚型间具有异质性,卵巢高级别浆液性癌、卵巢子宫内膜样癌、卵巢透明细胞癌及卵巢低级别浆液性癌组织中,B7-H3阳性率分别为92.5%(149/161)、15/16、11/11和2/4。(2)与B7-H3低表达的卵巢癌患者相比,高表达患者的PFS时间显著缩短( P=0.027)。多因素Cox回归分析表明,B7-H3高表达是影响卵巢癌患者PFS时间的独立危险因素( HR=1.884,95% CI为1.067~3.328, P=0.029)。进一步按组织学类型及BRCA基因突变状态进行分层分析显示,在卵巢高级别浆液性癌和BRCA基因突变的人群中,B7-H3高表达与PFS时间缩短有关( P均<0.05),而在非卵巢高级别浆液性癌(包括卵巢子宫内膜样癌、卵巢透明细胞癌及卵巢低级别浆液性癌)或BRCA基因未突变的患者中,未观察到该关联具有统计学意义( P均>0.05)。(3)mIF结果证实,B7-H3表达水平与叉头框蛋白P3(FOXP3) +调节性T淋巴细胞的浸润水平呈正相关( r=0.38, P<0.001),与CD 8+ T淋巴细胞( r=-0.29, P=0.004)及CD 86+抗原呈递细胞( r=-0.22, P=0.028)的浸润水平呈负相关。 结论:B7-H3在卵巢癌组织中广泛表达,且其表达水平具有组织学亚型异质性。B7-H3高表达是卵巢癌患者PFS时间缩短的独立危险因素,并参与免疫抑制微环境的形成。B7-H3可能作为卵巢癌预后评估的潜在生物标志物及免疫治疗靶点。
Abstract:
Objective:To analyze the expression level of B7 homolog 3 (B7-H3) in malignant epithelial ovarian tumor (ovarian cancer) tissues, and its correlations with clinicopathological characteristics, progression-free survival (PFS), and infiltration levels of immune cell subsets in patients.Methods:A total of 192 patients with ovarian cancer admitted to the First Affiliated Hospital of Nanjing Medical University from September 2020 to December 2024 were enrolled in this study. The expression level of B7-H3 in ovarian cancer tissues was detected by immunohistochemistry. The relationship between B7-H3 and the pathological characteristics of patients was analyzed by univariate and multivariate Cox regression analysis, and the effect of B7-H3 on PFS of patients with ovarian cancer was evaluated. Multiplex immunofluorescence was applied to analyze the infiltration levels of different immune cell subsets and their correlations with B7-H3 expression.Results:(1) The overall positive rate of B7-H3 in ovarian cancer tissues was 92.1% (177/192), and its expression exhibited heterogeneity across different histological subtypes. The positive rates of B7-H3 were 92.5% (149/161), 15/16, 11/11, and 2/4 in high-grade serous ovarian carcinoma, endometrioid ovarian carcinoma, ovarian clear-cell carcinoma, and low-grade serous ovarian carcinoma, respectively. (2) Compared with ovarian cancer patients with low B7-H3 expression, patients with high B7-H3 expression had significantly shorter PFS ( P=0.027). Multivariate Cox regression analysis revealed that high B7-H3 expression was an independent risk factor for PFS in patients with ovarian cancer ( HR=1.884, 95% CI: 1.067-3.328, P=0.029). Further stratified analysis according to histological subtype and BRCA gene mutation status demonstrated that high B7-H3 expression was associated with shortened PFS in patients with high-grade serous ovarian carcinoma or BRCA-mutated tumors (all P<0.05). However, such association was not statistically significant in patients with non-high-grade serous ovarian carcinoma (including endometrioid ovarian carcinoma, ovarian clear-cell carcinoma, and low-grade serous ovarian carcinoma) or BRCA wild-type status (all P>0.05). (3) Multiplex immunofluorescence results confirmed that B7-H3 expression level was positively correlated with the infiltration level of forkhead box protein P3 (Foxp3) + regulatory T lymphocytes ( r=0.38, P<0.001). B7-H3 expression was negatively correlated with the infiltration levels of CD 8+ T lymphocytes ( r=-0.29, P=0.004) and CD 86+ antigen-presenting cells ( r=-0.22, P=0.028). Conclusions:B7-H3 is widely expressed in ovarian cancer with heterogeneous expression across histological subtypes. High B7-H3 expression serves as an independent risk factor for shortened PFS in ovarian cancer patients and participates in the formation of an immunosuppressive tumor microenvironment. B7-H3 might act as a potential biomarker for prognostic evaluation and a therapeutic target for immunotherapy in ovarian cancer.